Alnylam Pharmaceuticals Inc (NASDAQ:ALNY)
| 150.82 Delayed Data As of Jul 05 |  +2.48 / +1.67%Today’s Change | 117.58 Today|||52-Week Range 212.00 | -11.06% Year-to-Date |
Latest ALNY News | Press Releases
No recent news for Alnylam Pharmaceuticals Inc.
Today’s Trading
| Previous close | 148.25 |
| Today’s open | 146.96 |
| Day’s range | 145.06 - 151.22 |
| Volume | 800,217 |
| Average volume (3 months) | 880,512 |
| Market cap | $17.9B |
Data as of 4:00pm ET, 07/05/2022
Growth & Valuation
| Earnings growth (last year) | +3.54% |
| Earnings growth (this year) | +6.90% |
| Earnings growth (next 5 years) | +38.33% |
| Revenue growth (last year) | +71.31% |
| P/E ratio | NM |
| Price/Sales | 23.79 |
| Price/Book | 30.29 |
Competitors
| Today’s change | Today’s % change | |
|---|---|---|
| INCYIncyte Corp | +1.58 | +2.03% |
| CTLTCatalent Inc | -0.01 | -0.01% |
| HZNPHorizon Therapeutics... | +1.92 | +2.38% |
| VTRSViatris Inc | -0.21 | -1.96% |
Data as of 4:00pm ET, 07/05/2022
Financials
| Next reporting date | August 2, 2022 |
| EPS forecast (this quarter) | -$1.63 |
| Annual revenue (last year) | $844.3M |
| Annual profit (last year) | -$852.8M |
| Net profit margin | -101.01% |
Profile
Sector Health Technology |
Industry Pharmaceuticals: Major |
No executives to display |
Corporate headquarters Cambridge, Massachusetts |
Forecasts
